Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.00 1.58% 386.00 386.00 396.00 394.00 370.00 380.00 118,043 16:19:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 301

Silence Therapeutics Share Discussion Threads

Showing 50501 to 50523 of 50925 messages
Chat Pages: Latest  2025  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  Older
DateSubjectAuthorDiscuss
02/4/2019
18:53
Surely we're due a decent bounce aren't we? Hope this is the start of it.
1gw
02/4/2019
08:25
Definitely a buyer around. 50k now on the order book at 46p
callumross
01/4/2019
12:52
Someone certainly wants stock. 100k just been placed on the order book at 42.6p.
callumross
28/3/2019
16:09
My employer's SIPP contribution comes through then
volsung
27/3/2019
17:00
I will be averaging down on or around 8th April
volsung
26/3/2019
18:25
Anyone brave enough to average down?
djnzloop
22/3/2019
12:58
Fine,could you comment on the huge difference between share prices over the last year,whilst they are both in the same fundamental business.What is Arrowhead doing that Silence is not.Maybe they could replicate.
tshirley12
22/3/2019
11:58
"What other assets does Silence have other than their.I.P. Is there a danger of Silence running out of funding,and when." Cash of £26.5m as at 31/12/18 and enough to take them into 2nd half 2020. "What happened to ATUO27". - discontinued. "What other assets does Silence have other than their.I.P." Cash of £26,5m plus milestone and licensing agreements for 2 Quark products "As anybody got any idea how much they received from their Alnylam agreement" Between 0.33% and 1% of Patisiran sales in Europe up till 2023. Actual amount depends on level of Patisiran sales. "As there's no sign of a takeover,are there any possibilities of a merger with anybody" - who knows!
callumross
22/3/2019
10:32
A few questions,would appreciate any comments.Firstly over the last year the share price has fallen from a peak of 250p to less than 50p.today.Whilst Arrowheads share price as more or less quadrupled,what is Silence doing that is fundamentally different to justify the crash. What other assets does Silence have other than their.I.P. Is there a danger of Silence running out of funding,and when. As anybody got any idea how much they received from their Alnylam agreement. What happened to ATUO27. As there's no sign of a takeover,are there any possibilities of a merger with anybody. Now waiting on the results from Quark,if this doesn't go as well as hoped, where does that leave us. As I said I would appreciate any comments as I am looking at all avenues before I decide to bail out.
tshirley12
15/3/2019
19:11
I was wondering if we had been played with that Ali move. Just as all the C level quits he flies the flag big time ....
djnzloop
15/3/2019
17:08
Yes, it's not encouraging is it, especially on the patent climbdown? I cling to the hope that Ali knew what he was doing when he increased his holding materially last year (5th October rns). A good announcement from Quark around their interpretive results would help to restore my faith that there is at least some basis to the science at this point.
1gw
12/3/2019
19:04
Arrowhead now at around $20 & current management folding before the finish line after £4 mil legal fee spend. This lot look destined to waste what's left of the pot & then hope the spend will enable inroads to new jobs. I reckon the 2.30 at Chepstow would be a fairer bet
djnzloop
11/3/2019
10:02
Quark completed dosing of 594 patients in a Phase III study for delayed graft function (DGF) following kidney transplantation in January 2018, with first interpretative results anticipated imminently
callumross
11/3/2019
07:20
'We remain focussed and determined to be responsive to shareholder value and also chart the right course for our business to see appropriate growth, and development. To this end we continue to assess a number of options in addition to our organic plan which we believe would be additive to the Company's future growth prospects and shareholder value' ..........zzzzzzzzzzzzzzzzz
soundbuy
08/3/2019
07:41
Note that Quark have moved into a full phase 3 in kidney function. Did SLN get any milestone? hTtps://www.clinicaltrials.gov/ct2/show/NCT03510897?term=NCT03510897&rank=1
waterloo01
07/3/2019
12:17
Any ideas about results monday ?
tarlok
07/3/2019
08:26
Silent as the grave
volsung
14/2/2019
12:31
www.optcongress.com/oligonucleotide SLN and Quark presenting here
rnainvestor
14/2/2019
12:23
www.optcongress.com
rnainvestor
14/2/2019
12:22
www.optcongress.com/oligonucleotide
rnainvestor
05/2/2019
15:18
Dear SLN Could you do a VAL soon? Kind regards volsung
volsung
31/1/2019
15:41
Think they've shut up shop
djnzloop
31/1/2019
14:43
Isn't it about time we heard something about Quark's trial?
1gw
Chat Pages: Latest  2025  2024  2023  2022  2021  2020  2019  2018  2017  2016  2015  2014  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191113 04:20:22